secwatch.observer — SEC 8-K summary
======================================

Issuer:     Outlook Therapeutics, Inc. (OTLK)
CIK:        0001649989
Form:       8-K
Filed at:   2026-05-29T20:30:49+00:00
Accession:  0001104659-26-068306
Event type: debt
Sentiment:  negative
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Outlook Therapeutics sells 8.54M shares to GMS Ventures in registered direct offering
--------------------------------------------------------------------------------

- 8,539,709 shares of common stock sold to GMS Ventures and Investments under a securities purchase agreement dated May 28, 2026.
- Offering made via effective S-3 shelf registration statement (File No. 333-278340).
- No per-share price or gross proceeds disclosed in the filing.
- Shares issued under a registered direct offering; closing expected on or about May 29, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649989/000110465926068306/0001104659-26-068306-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649989/000110465926068306/tm2615979d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-068306

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer